Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-17

NCT03462576 is registered in ClinicalTrials.gov with Meridian Bioscience, Inc. as lead sponsor.

NCT NCT03462576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03462576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Companion Protocol for the ¹³C-Methacetin Breath Test Using the BreathID® MCS System for Conatus Phase 2 Study of Emricasan, an Oral Caspase Inhibitor, Under Protocol IDN-6556-17
Lead sponsor
Meridian Bioscience, Inc.
Phase
Not reported
Overall status
Terminated
Start date
June 28, 2017
Completion date
July 15, 2019
Enrollment
199 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

decompensated cirrhosis